Cost Effectiveness, Chemotherapy, and the Clinician

Published In: Breast Cancer Research and Treatment, v. 114, no. 3, April 2009, p. 597-598

Posted on RAND.org on April 01, 2009

by J. J. Griggs, Melony E. Sorbero

Read More

Access further information on this document at Springer

This article was published outside of RAND. The full text of the article can be found at the link above.

Economic evaluations of health care can be used by policy makers and other decision makers to compare the cost effectiveness of different treatment strategies and to make decisions about the allocation of scarce resources, such as dollars spent on health care. This commentary focuses on two journal articles address the cost effectiveness of docetaxel, doxorubicin and cyclophosphamide (TAC) compared to 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in the adjuvant treatment of breast cancer using data from a clinical trial, BCIRG 001 Both studies found that, despite the higher costs of TAC, the greater efficacy of this regimen in patients enrolled in BCIRG 001 led to a favourable cost effectiveness ratio.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.